Subject: FDA Clears Human Trials Of Possible AIDS Vaccine
Date: Published: 11/21/90 (37 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Technology:
    FDA Clears Human Trials
    Of Possible AIDS Vaccine

    WASHINGTON -- The Food and Drug Administration approved
 human clinical trials of an experimental vaccine for acquired
 immune deficiency syndrome, developed by the National
 Institutes of Health and the U. S. affiliate of Immuno AG of
 Vienna.
    The experimental vaccine, the sixth to enter U. S. tests,
 is a gene-spliced piece of the human immunodeficiency virus
 known as the gp 160 envelope glycoprotein.  The vaccine was
 the product of a research partnership between the National
 Institute of Allergy and Infectious Diseases and the National
 Cancer Institute, both units of the NIH, working with
 Immuno-U. S. Inc. of Rochester, Minn.
    In previous animal studies, the synthetic vaccine
 protected a chimpanzee from infection for almost three years.
 However, three other vaccinated animals became infected when
 exposed later to high doses of live virus.
    Initially, 60 healthy volunteers will be immunized in the
 safety studies.  The studies, under sponsorship of NIAID, will
 take place at St. Louis University School of Medicine, St. 
 Louis; Johns Hopkins Center for Immunization Research,
 Baltimore; University of Washington School of Medicine,
 Seattle; University of Rochester School of Medicine,
 Rochester, N. Y. ; and Vanderbilt University Medical Center,
 Nashville, Tenn.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]